Literature DB >> 20012962

The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis.

Pinar Borman, Figen Ayhan, Esma Ceceli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20012962     DOI： 10.1007/s00296-009-1283-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  4 in total

1.  The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.

Authors:  N Barkham; K O Kong; A Tennant; A Fraser; E Hensor; A M Keenan; P Emery
Journal:  Rheumatology (Oxford)       Date:  2005-08-16       Impact factor: 7.580

2.  Functional disability and quality of life in patients with ankylosing spondylitis.

Authors:  Elif E Bostan; Pinar Borman; Hatice Bodur; Nurdan Barça
Journal:  Rheumatol Int       Date:  2002-10-30       Impact factor: 2.631

3.  Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  H Bodur; S Ataman; L Akbulut; D Evcik; V Kavuncu; T Kaya; R Günaydin; B Kuran; N Kotevoğlu; A Bal; E Aydoğ; Z Altay; H Uğurlu; H Kocabaş; N Olmez; P Yazgan; S Gürsoy; E Madenci; S Ozel; S U Delialioğlu
Journal:  Clin Rheumatol       Date:  2008-03-21       Impact factor: 2.980

4.  An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.

Authors:  T Pham; R Landewé; S van der Linden; M Dougados; J Sieper; J Braun; J Davis; M Rudwaleit; E Collantes; R Burgos-Vargas; J Edmonds; I Olivieri; I van der Horst-Bruinsma; H Mielants; M Stone; P Emery; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2006-02-07       Impact factor: 19.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.